Floatz logo

Tnx-102 Sl

Major Depressive Disorder (MDD)

Tonix Pharmaceuticals, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

234 Active assets in the Major Depressive Disorder (MDD) cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Tnx-102 Sl is also rated in:

long COVID-19Dormant
B
Indicative ·
57 / 100
View asset →
COVID-19Dormant
B
Indicative ·
57 / 100
View asset →
depressive disorderDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →